RICHMOND, Va. — Haleon, a global company behind home healthcare products like Advil, Tums and Aquafresh, announced Monday its plan to upgrade its Richmond research and development facility.

Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3% ...

The UK-based pharmaceutical company Haleon will invest $54.2 million to upgrade its R&D facility in Richmond, which has helped birth or grow products such as Advil, Emergen-C and Robitussin.

Haleon PLC HLN shares rallied 2.06% to £3.87 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.77% to 8,767.80. Haleon ...

Shares of Haleon plc (NYSE:HLN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat ...

In a report released today, David Hayes from Jefferies maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of p450.00. David Hayes has given his Buy rating due to ...

(Reuters) -Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner ...

In an interview with Gulf Business, Charles Leslie, global business lead for the Pain Portfolio & Systemics at Haleon ... how we view health and wellness. One of the most noticeable trends ...

The company said the investment is in addition to its 300 million pound ($372.5 million) annual spending in R&D. The Richmond facility is one of the three R&D centres of excellence for Haleon, along ...

(RTTNews) - Pfizer Inc. (PFE) Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare company, at 357 pence per share or approximately $ ...